These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 28467313

  • 21. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y, Yuki H, Hirata S, Ide K, Nakata H, Miyakawa T, Matsuno N, Nosaka K, Yonemura Y, Kawaguchi T, Hata H, Mitsuya H, Okuno Y.
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [Abstract] [Full Text] [Related]

  • 22. Type 1 Cryoglobulinemic Vasculitis Due to Monoclonal Gammopathy of Undetermined Significance Successfully Treated by Bortezomib Plus Dexamethasone.
    Kikuchi R, Onozawa M, Nagai J, Okada S, Hasegawa Y, Ohigashi H, Mitamura S, Maeda T, Takakuwa E, Fujieda Y, Goto H, Hashimoto D, Matsuno Y, Teshima T.
    Intern Med; 2024 Feb 15; 63(4):541-545. PubMed ID: 37316269
    [Abstract] [Full Text] [Related]

  • 23. [Skin disorders associated with monoclonal gammopathies].
    Houtman CJ, Genders RE, von dem Borne PA, Vermeer MH.
    Ned Tijdschr Geneeskd; 2014 Feb 15; 158():A6717. PubMed ID: 24780569
    [Abstract] [Full Text] [Related]

  • 24. [Monoclonal gammopathies of undetermined significance called "MGUS"].
    Clément F.
    Schweiz Med Wochenschr; 1989 Jul 11; 119(27-28):970-8. PubMed ID: 2508215
    [Abstract] [Full Text] [Related]

  • 25. Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report.
    Noto R, Kamiura N, Ono Y, Tabata S, Hara S, Yokoi H, Yoshimoto A, Yanagita M.
    BMC Nephrol; 2017 Apr 06; 18(1):127. PubMed ID: 28385149
    [Abstract] [Full Text] [Related]

  • 26. Good treatment-free survival of monoclonal gammopathy of undetermined significance associated pure red cell aplasia after bortezomib plus dexamethasone.
    Zhang L, Chen N, Xu Z, Liang Q, Pan H, Zhao J, Fang L, Shi J.
    Blood Cells Mol Dis; 2021 Jul 06; 89():102573. PubMed ID: 33957358
    [Abstract] [Full Text] [Related]

  • 27. [Monoclonal gammopathy of (un)known significance].
    Steinhardt M, Kortüm M, Einsele H, Rasche L.
    Dtsch Med Wochenschr; 2022 Jun 06; 147(11):675-682. PubMed ID: 35636418
    [Abstract] [Full Text] [Related]

  • 28. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
    Bergón E, Miravalles E, Bergón E, Miranda I, Bergón M.
    Clin Chem Lab Med; 2005 Jun 06; 43(1):32-7. PubMed ID: 15653439
    [Abstract] [Full Text] [Related]

  • 29. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
    Campbell JP, Heaney JLJ, Pandya S, Afzal Z, Kaiser M, Owen R, Child JA, Cairns DA, Gregory W, Morgan GJ, Jackson GH, Bunce CM, Drayson MT.
    Lancet Haematol; 2017 Dec 06; 4(12):e584-e594. PubMed ID: 29146225
    [Abstract] [Full Text] [Related]

  • 30. A rare case of IgE kappa monoclonal gammopathy of undetermined significance identified in a Swedish female.
    Fager Ferrari M, Lemonakis K, Förnvik Jonsson M.
    Scand J Clin Lab Invest; 2021 Sep 06; 81(5):385-388. PubMed ID: 34097568
    [Abstract] [Full Text] [Related]

  • 31. Monoclonal gammopathies of undetermined significance.
    Kyle RA, Rajkumar SV.
    Best Pract Res Clin Haematol; 2005 Sep 06; 18(4):689-707. PubMed ID: 16026745
    [Abstract] [Full Text] [Related]

  • 32. Light-Chain Deposition Disease Successfully Treated with Bortezomib in an Elderly Patient: A Case Report and Review of the Literature.
    Wada Y, Iyoda M, Saito T, Arai-Nunota N, Iseri K, Tomita E, Ikeda M, Yamaguchi Y, Shibata T.
    Intern Med; 2015 Sep 06; 54(22):2893-8. PubMed ID: 26568005
    [Abstract] [Full Text] [Related]

  • 33. [Starry erythema under bortezomib].
    Ducours M, Lazaro E, Machelart I, Greib C, Viallard JF, Rivière E.
    Presse Med; 2019 Oct 06; 48(10):1187-1189. PubMed ID: 31669006
    [No Abstract] [Full Text] [Related]

  • 34. Primary systemic amyloidosis with skin and cardiac involvement: a case report.
    Trajber Horvat A, Trčko K, Jurčić V, Marko PB.
    Acta Dermatovenerol Alp Pannonica Adriat; 2018 Mar 06; 27(1):45-47. PubMed ID: 29589647
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F, Delbes S, Sirac C, Pourreau F, Puyade M, Desport E, Jaccard A, Fermand JP, Touchard G.
    Presse Med; 2012 Mar 06; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [Abstract] [Full Text] [Related]

  • 37. The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients.
    Cao XX, Meng Q, Mao YY, Su W, Zhen JF, Shen KN, Zhang CL, Huang XF, Duan MH, Zhang W, Zhu TN, Cai HC, Chen M, Zhou DB, Li J.
    Leuk Res; 2016 Jul 06; 46():85-8. PubMed ID: 27232065
    [Abstract] [Full Text] [Related]

  • 38. Benign monoclonal gammopathy turning to AL amyloidosis after kidney transplantation.
    Dysseleer A, Michaux L, Cosyns JP, Goffin E, Hermans C, Pirson Y.
    Am J Kidney Dis; 1999 Jul 06; 34(1):166-9. PubMed ID: 10401033
    [Abstract] [Full Text] [Related]

  • 39. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
    Vial G, Lafargue A, Mercié P, Duffau P, Ribeiro E.
    Rev Med Interne; 2022 Nov 06; 43(11):673-676. PubMed ID: 35934598
    [Abstract] [Full Text] [Related]

  • 40. [Temporal artery syndrome in amyloidosis AL associated with myeloma].
    Hamidou M, Buzelin F, Rojouan J, Barrier JH, Briseau JM, Grolleau JY.
    Rev Med Interne; 1991 Nov 06; 12(4):306-8. PubMed ID: 1759073
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.